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ABSTRACT
Introduction: Surveys of long-term health and
developmental outcomes of children born to mothers
with systemic lupus erythematosus (SLE) have
suggested an increase in learning disabilities among
these children. We performed this observational study
to investigate the relationship between maternal
autoantibodies and antiphospholipid antibody
syndrome (APS) in maternal lupus patients and
neurocognitive development among their offspring.
Methods: SLE mothers with at least one live birth
postlupus diagnosis were enrolled. Data on maternal
medical/obstetric history and children’s perinatal/
medical history were collected by structured interview
and medical record reviews. The primary outcome was
requirement for special educational (SE) services,
a proxy for developmental delays. Multiple logistic
regression modelling was used to examine
associations between APS and autoantibodies with SE
usage, accounting for SLE disease severity and
potential confounders.
Results: Data on 38 mothers and 60 offspring were
analysed: SE service usage was reported for 15 of 60
(25%) offspring. Maternal APS history was
significantly associated with increased use of SE
services among offspring, including after adjustment
for lupus anticoagulant (LA) positivity and potential
confounders (OR 5.5–9.4 for delays age ≥2; p<0.05).
The presence of LA, but not other antiphospholipid
antibodies, was also associated with increased SE
services usage.
Conclusions: Maternal APS and LA were
independently associated with increased usage of
special educational services among offspring of
women with SLE.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a sys-
temic autoimmune disorder for which females
experience disproportionate risk, particular
from the reproductive years onward.1 2 SLE
pregnancies are associated with increased risk
of adverse obstetric outcomes including
preterm labour and pre-eclampsia.3 The pres-
ence of antiphospholipid antibodies (aPL)
and/or a history of renal disease or hyperten-
sion are known to affect the course of lupus
pregnancies as well.4–8 aPLs are associated with
recurrent fetal loss and pre-eclampsia,8 and
are reported among a substantial proportion
of SLE patients: approximately 30% of
lupus patients are estimated to have the lupus
anticoagulant (LA), 23–48% anticardiolipin
antibodies, and 20% anti-β2-glycoprotein
antibodies.9 10
Most studies published about lupus pregnan-
cies have focused on obstetric and neonatal
outcomes of offspring. As improvements in
diagnosis and management over the last
several decades have allowed more women
with lupus the opportunity to achieve success-
ful pregnancies,11 there has been growing
interest in the long-term outcomes of children
born to mothers with SLE, including any
neuropsychological and cognitive outcomes
that may be impacted by SLE and its treatment
during pregnancy. Growing evidence suggests
increased rates of learning delays among off-
spring of mothers with SLE,12–17 and associa-
tions between autism spectrum disorders,
dyslexia and other neurocognitive dysfunction
and speciﬁc maternal autoantibodies (anti-Ro,
anti-La, aPLs).18–22 We performed this study in
KEY MESSAGES
▸ This research adds to a growing body of evi-
dence suggesting that children born to mothers
with lupus, in this case those with maternal anti-
phospholipid antibodies, may be at increased
risk for developmental delays.
▸ More research into screening for early childhood
developmental delays in these children is
warranted.
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order to further investigate the relationship between anti-
phospholipid antibodies in a cohort of women with lupus,
and neurocognitive development among their offspring.
METHODS
Study population
This study included women attending rheumatology out-
patient clinics at the University of Michigan Health System,
including patients enrolled in the Michigan Lupus Cohort.
As described in more detail elsewhere,14 study enrolment
took place over the calendar period December 2008 to
November 2010. SLE patients were eligible if they met ≥4
American College of Rheumatology (ACR) criteria for SLE
23 24 prior to at least one pregnancy, and had at least one
live birth following SLE diagnosis. This research was
approved by the University of Michigan Institutional
Review Board. Written informed consent was obtained
from participating mothers; assent or consent was obtained
from the offspring for children aged 10–17 years old.
Data collection
Maternal history
Data were collected from the mothers during an inter-
view with a maternal fetal medicine investigator, using a
structured format that included medical and obstetric
history. Data elements included maternal medical history,
including details of SLE history, such as associated mani-
festations and organ involvement. Data were also col-
lected on general historical medical information,
including history of hypertension or cardiovascular
events. A detailed history of medication exposures during
pregnancy was obtained. Laboratory data, including
results of renal biopsies, if applicable, were also recorded.
Antiphospholipid antibodies and syndrome
History of antiphospholipid antibody syndrome (APS)
was deﬁned according to the Sydney classiﬁcation cri-
teria developed by expert consensus agreement in
2006,25 which represented an updated version of the
Sapporo criteria for APS developed in 1999.26 Individual
antiphospholipid antibodies were recorded, as described
below. IgG and IgM isotypes of anticardiolipin (aCL),
and β-2-glycoprotein 1 (β2GP1), were classiﬁed as posi-
tive if greater than the 99th percentile at our institution,
on two or more occasions, at least 12 weeks apart, prior
to, or during the study pregnancy, which corresponded
to the following cut-offs: aCL IgG (≥22 GPL); aCL IgM
(≥25 MPL); β2GP1 IgG (≥24 U/mL); β2GP1 IgM
(≥26 U/ML). The LA was identiﬁed either by prolonga-
tion of activated partial thromboplastin time or dilute
Russell’s viper-venom time (dRVVT) with a positive con-
ﬁrmatory test.
Offspring history
Medical and developmental histories of the offspring of
the maternal participants were performed, including
antenatal, delivery, perinatal and paediatric histories, as
described elsewhere.14 The study instrument (question-
naire) was, in part, designed to capture data on peri-
natal and early life health up to age 2 years, so data
collection was categorised by age <2 years, or 2 years and
above. Brieﬂy, our primary outcome measure was usage
of special educational (SE) services, based on maternal
report of recommendation by a physician or educator
due to concern for delay in a child’s cognitive, physical
or social maturity compared with established
age-appropriate norms. Speech or hearing delays, diag-
nosis of attention-deﬁcit hyperactivity disorder (ADHD),
or any special educational need prompting a teacher or
paediatrician to initiate referral for SE services
(eg, occupational or speech therapy, behavioural coun-
selling, tutoring) were recorded. Referrals were cate-
gorised according to whether they occurred at any age,
during the ﬁrst 2 years of life, and/or from age 2 years
onward.
Statistical analysis
Baseline summary statistics were computed as mean and
SD for continuous variables, or frequency and propor-
tion for categorical variables. Variables were assessed for
normality, and non-parametric statistics were used if
appropriate. Demographic characteristics of mothers
among the groups with and without SE services usage
were checked for comparability. The outcomes were
examined based on four categories of possible education
needs: any need, need for service prior to age two, after
age two, or speech delay. We tested baseline character-
istics of the offspring (maternal antibody proﬁle, mater-
nal SLE duration, maternal hypertension, pregnancy
complications, gestational age, birth weight, congenital
heart block, and sex of child) among those children
with and without each educational need type using
Fisher’s exact test and the Wilcoxon rank-sum test.
Using logistic regression, we computed ORs and 95%
CIs to examine the association between maternal APS or
the presence of antiphospholipid antibodies and referral
or need for SE services.
To adjust for other covariates, we used standard and
exact multivariable logistic regression; due to the limited
sample size, separate bivariate models were used to
adjust for covariates of interest, since models with more
than two covariates would be unstable. Model ﬁt was
assessed using the Hosmer–Lemeshow test. In order to
account for potential correlation due to multiple births
from some mothers, we also ﬁt models using a reduced
sample consisting of only one randomly selected child
from each mother, and conducted a simulation of 1000
permutations of mother–child combinations in order to
examine the distribution of p values from these models.
All statistical analyses were performed in Stata V.11.1.27
RESULTS AND DISCUSSION
Eighty-ﬁve women were screened for participation in the
study, of whom 38 met eligibility criteria and enrolled in
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this study. Among these 38 mothers, 60 eligible offspring
were included. The mean age range of the children at
the time of data collection was 6.6 years (SD±3.8).
Maternal characteristics of the study participants are
summarised in table 1. We did not ﬁnd signiﬁcant differ-
ences in maternal characteristics, including race, age, or
educational level, between the mothers of the children
who were referred for SE services compared to those
who were not. Among the offspring included in this ana-
lysis, there were 56 singleton births, and 2 sets of twins.
There was no usage of SE services reported for the chil-
dren of the twin pregnancies. Of the 60 children, 62%
were female, 6 (10%) were born at gestational age of
less than 32 weeks, 17 (28%) between 32 and 37 weeks,
and 15 (25%) were small for gestational age. There was
one case of congenital heart block without any special
educational needs.
SE services usage overall occurred in 15 (25%) of the
60 children. The most prevalent type of educational need
was for speech delay requiring speech therapy in 12
(20%) of the children in this study. Attention-deﬁcit dis-
order was reported for 3 (5%) of the 60 children. When
categorised according to age of intervention, 10 of 60
(17%) children were referred in the ﬁrst 2 years of life,
and 14 (23%) from age 2 years onward, with 9 children
referred in both age categories.
We explored several factors that had been previously
suspected to be associated with developmental delays.
We did not detect associations between maternal clinical
features, such as SLE disease duration, lupus nephritis
or ﬂare during pregnancy, or pre-eclampsia. Likewise,
gestational age, birth weight, and small for gestational
age, were not detected to be associated with SE usage.
Investigation of autoantibodies (table 2) revealed that
maternal APS and LA positivity were each signiﬁcantly
associated with need for SE services: APS was signiﬁ-
cantly associated with any delay (p=0.04) and delays
≥2 years (p=0.01). Among particular antiphospholipid
antibodies, LA was signiﬁcantly associated with delays at
<2 years (p=0.01), whereas aCLs and anti-β2GP1 were
not detected to be associated with delays.
We further investigated the association between APS and
SE usage using logistic regression modelling (table 3).
Crude ORs were 5.1 (95% CI 1.2 to 22.6) for the association
with any use of SE services, and 7.8 (95% CI 1.6 to 38.6) for
the association with usage from age 2 years onward.
Magnitudes of association remained similar for bivariate
models adjusting for pregnancy duration, small for gesta-
tional age, and maternal education. There were not enough
cases of SE services usage in the ﬁrst 2 years to model those
outcomes in multivariable models. In order to account for
potential correlation between offspring of the same mother,
we did a simulation of 1000 permutations of mother–child
combinations using exact logistic regression. For the associ-
ation between APS and SE services needs, 14.8% of the 1000
random samples had associated p values of <0.05, and
24.6% generated a p value of <0.10, supporting the conclu-
sions from the models that included all 60 offspring.
When simultaneously modelling APS and LA positivity,
positive associations between APS and SE services usage
persisted, though slightly lower in magnitude—OR 3.8
(95% CI 0.8 to 18.1) for any delay and 5.5 (95% CI 1.1
to 28.7) for delays age 2 years onward. The stability in
effect estimates for SE services categorised as any delay
or delays from age 2 years onward supports an inde-
pendent association between APS and SE services needs
even after accounting for LA positivity.
We controlled for multiple potential confounders,
including accounting for underlying disease severity by
using propensity scoring, and controlling for variables
related to lupus disease activity, perinatal complications
(including intrauterine growth restriction), and effects of
various medications commonly used in treating SLE and
APS during pregnancy. One of these medications, inject-
able heparin, is indicated for treatment of pregnant
women with APS, so we therefore explored whether the
APS association was modiﬁed by this variable. Overall, ﬁve
of the mothers were taking heparin during pregnancy, of
whom two were mothers with secondary APS. There was
no association between heparin and SE services usage
Table 1 Maternal characteristics among mothers with
SLE (n=38)
Characteristic
n (%) or median
(IQR)
Maternal race
African–American 5 (13)
Caucasian 25 (66)
Asian 3 (8)
Other 5 (13)
Marital status
Married 32 (84)
Divorced/single/separated 6 (16)
Maternal education (years) 16 (16, 18)
Country of birth
USA 34 (89)
Other 4 (11)
Number of pregnancies 2 (2, 3)
Number of children 2 (1, 2)
SLE features*
Antiphospholipid antibody
syndrome (APS)
7 (18)
Malar rash 24 (63)
Discoid rash 3 (8)
Photosensitivity 24 (63)
Oral ulcers 18 (47)
Arthritis 36 (95)
Serositis 15 (39)
Renal disorder 17 (45)
WHO class ≥ III 12 (32)
Neurological disorder 11 (29)
Hematological disorder 23 (61)
Immunological disorder 31 (82)
Antinuclear antibody 34 (89)
*SLE features defined according to ACR classification for SLE,
except for APS which was according to Sydney criteria.
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based on univariate modelling in the offspring of these
women, and when adjusted for heparin used, the APS
association with SE services was similar to the crude esti-
mate. Another medication used frequently during lupus
pregnancies is azathioprine, and we previously demon-
strated in this study population that in utero azathioprine
exposure was associated with increased usage of SE ser-
vices.14 We therefore adjusted for azathioprine use during
pregnancy, and maternal APS remained signiﬁcantly asso-
ciated with need for SE services.
CONCLUSIONS
In this study of 60 children born to mothers with lupus,
maternal APS was associated with a threefold to eightfold
increase (depending on the category of delay and other cov-
ariates included in the modelling) in the requirement for
special educational (SE) services, a proxy for developmental
delays in offspring. The association between maternal APS
and need for SE services was robust across models, including
after adjustment for recognised risk factors for future learn-
ing disorders, particularly prematurity and low birth
weight.28 29 The population we studied included women
with a wide range of lupus disease activity during pregnancy,
and a substantial number with a history of lupus nephritis
and extrarenal lupus, many of whom had sufﬁcient disease
activity to require immunosuppressive therapy during their
pregnancy. However, maternal lupus disease activity and
other maternal factors including pre-eclampsia, history of
hypertension, or lupus nephritis prior to pregnancy did not
Table 2 Special educational (SE) service needs corresponding to maternal autoantibodies and antiphospholipid antibody
syndrome
No SE services SE services
Referent (n=45) Any (n=15) Age <2 (n=10) Age ≥2 (n=14)
Autoantibody features
APS 4 (9) 5 (33)* 3 (30) 5 (36)**
aPLs
LA 16 (36) 11 (73) 9 (90)** 10 (71)
aCL—IgG 9 6 5 5
aCL—IgM 0 0 0 0
anti-β2GPI—IgG 0 0 0 0
anti-β2GPI—IgM 1 0 0 0
Anti-Ro/SSA 16 (36) 3 (20) 2 (20) 2 (14)
Anti-Ro among APS+ 1 (2) 1 (7) 0 (0) 1 (7)
Anti-La/SSB 8 (18) 1 (7) 0 (0) 1 (7)
Anti-La among APS+ 2 (4) 1 (7) 0 (0) 1 (7)
Propensity Score† 0.12 (0.19–0.15) 0.16 (0.10–0.30)* 0.16 (0.09–0.17) 0.18 (0.12–0.30)**
Data are presented as frequency (%) for categorical variables or median (IQR) for continuous variables.
*p<0.05;
**p≤0.01.
†Propensity score (for APS) uses non-fluorinated steroids, WHO class III and up for renal biopsy, and flare during pregnancy.
Table 3 Association between maternal antiphospholipid antibody syndrome (APS) and special educational (SE) services
requirement among offspring
Covariates
Any SE service (n=15) SE service age ≥2 years (n=14)
OR (95% CI) OR (95% CI)
APS (crude) 5.1 (1.2 to 22.6)* 7.8 (1.6 to 38.6)*
APS adjusted for:
+Pregnancy duration
(weeks)
4.1 (0.9 to 19.3) 6.7 (1.3 to 35.2)*
+Small for gestational age 5.0 (1.1 to 22.3)* 7.6 (1.5 to 38.3)*
+Maternal education
(years)
4.3 (0.9 to 19.8) 7.5 (1.4 to 39.1)*
+Lupus anticoagulant 3.8 (0.8 to 18.1) 5.5 (1.1 to 28.7)*
+Heparin 4.0 (0.9 to 18.5) 6.8 (1.3 to 35.1)*
+Pscore +AZA 4.2 (0.82 to 21.7) 9.4 (1.47 to 60.0)*
Lupus anticoagulant (crude) 4.0 (1.1 to 14.7)* 3.2 (0.9 to 12.1)
+APS 3.6 (0.9 to 13.8) 2.6 (0.7 to 10.5)
ORs represent the effect estimates for APS based on the crude (univariate) logistic regression models and additional bivariate logistic
regression models adjusted for the covariates listed.
*Indicates statistical significance (p<0.05).
APS, antiphospholipid antibody syndrome; DD, developmental delay.
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predict which children were more likely to be referred for
SE services, raising the question of whether aPLs themselves
affect fetal neurocognitive development, much as maternal
anti-Ro/SSA and anti-La, SSB antibodies target the antigenic
cells in the fetal conduction system.20 30
We examined the association of different classes of
aPLs with the need for SE services, and found that the
presence of LA, but not aCLs or anti-β2GP1 antibodies,
was associated with an increased need for SE services in
offspring; 90% of children in this study under age
2 years requiring SE services were born to mothers who
were LA positive. A potential mechanism for a heigh-
tened association between LA and usage of SE services
(beyond the other aPL subgroups) is unclear. However,
LA has been shown to have greater clinical relevance
than aCLs in predicting venous thrombosis in SLE
patients.31 Furthermore, recently published results from
the Predictors of Pregnancy Outcome: Biomarkers in
Antiphospholipid Antibody Syndrome and Systemic
Lupus Erythematosus (PROMISSE) study revealed a sig-
niﬁcant association between LA (but not the other
classes of aPLs) with adverse pregnancy outcomes,
including unexplained fetal death.32 However, triple aPL
positivity (LA, β2GP1, and anticardiolipin antibodies) in
association with a history of thrombosis has been sug-
gested to be a stronger predictor of adverse pregnancy
outcomes than positivity for any individual aPL.33
Our ﬁndings of maternal APS and LA positivity as sig-
niﬁcant predictors of SE service usage in offspring support
other studies of adverse neurodevelopmental outcomes in
offspring born to mothers with SLE as well as
APS.13 15 22 30 In one study in which standardised,
age-appropriate intelligence and performance tests were
administered to 47 children born to mothers with SLE,
investigators found that the children had normal IQ
scores, but those who had low scores in speciﬁc tests were
signiﬁcantly more likely to be born to mothers who were
positive for aPLs (3/3 vs 2/11; p=0.02), although the par-
ticular subtype of aPL was not stated.22 A 2008 study in
which children born to mothers with primary APS were
evaluated using standardised tests of intelligence and cog-
nitive abilities, found learning disability in 4 of 15 children,
though complications, such as prematurity and low birth
weight were not controlled for.21 A prospective European
registry following a cohort of children born to mothers
with APS (by Sapporo criteria) reported follow-up from
birth to age 5 years of 141 children in which 4 children
born to mothers with primary obstetric APS had clinical
features of autism and hyperactive behaviour (in 2 chil-
dren), feeding disorders, language delay, and growth
failure (in 1 child), axial hypotony (in 2 children) and psy-
chomotor delay (in 1 child).34 Results are inconsistent
regarding learning or developmental delays in children
born to mothers with anti-Ro and anti-La antibodies.20 We
did not ﬁnd any relationship between the presence of
anti-Ro or anti-La antibodies and increased rates of
usageof SE services in our study, nor did we ﬁnd differen-
tial risks for male compared to female offspring.
While our study did not include an external control
group, the Citizen’s Research Council of Michigan35 esti-
mates that approximately 14% K-12 students in the state
received special education services in 2010, a level which
is approximately half of what we observed in children
born to SLE mothers in our study population.
Furthermore, the most common category identiﬁed for
SE needs in children from the general Michigan popula-
tion was for speciﬁc learning disability and speech/lan-
guage impairment (60%); by comparison, we noted a
higher percentage of children in our study (12/15
(80%)) with a speech delay requiring speech therapy.
Our study is somewhat limited because the data were
acquired retrospectively, and the mothers’ recollections
of requirements for SE services or any associated devel-
opmental delays in their children could have resulted in
recall bias. However, we would not expect that APS in
the context of a complex disease such as lupus would
inﬂuence recollection one way or another. We were not
able to directly account for correlations between siblings
from the same mother due to small sample size, so
instead, we used a separate model which randomly
selected for one child from each mother, but further
reduced the sample size. We also observed that children
with a SE need in their ﬁrst 2 years of life were more
likely to have ADHD or further SE needs as older chil-
dren, so these children were included in both age cate-
gorisations of delays, resulting in a large degree of
overlap and signiﬁcance across multiple categorisations
for a given characteristic. Finally, because this was a
hypothesis-generating observational study, outcomes
were not based on standardised neurocognitive testing.
Future research incorporating formal neurocognitive
testing is needed in order to more fully characterise the
extent and predictors of developmental delays in this
population.
Strengths of our study include a population from a
well-characterised cohort of women with a wide range of
lupus disease activity, a signiﬁcant number of whom
required immunosuppressive, antimalarial and/or gluco-
corticoid therapy during their pregnancies. Because the
patients enrolled in this study were followed at the
University of Michigan, all laboratory assays were standar-
dised. The multidisciplinary research team involved in
this study consisted of rheumatologists and a maternal
fetal medicine specialist, whose extensive experience of
high-risk pregnancies allowed for the capture of accurate
data relating to the prenatal and perinatal periods.
Finally, we used a maternal report of SE usageas a proxy
variable for developmental delay in offspring, and con-
sider it to be a clinically relevant endpoint, prompting
intervention from a healthcare or educational provider.
This pilot study of long-term outcomes of children
born to mothers with lupus is consistent with a growing
body of literature supporting a potentially pathologic
association of transplacental maternal antiphospholipid
autoantibodies and impaired neurocognitive develop-
ment in offspring. These ﬁndings should raise the index
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of suspicion among paediatricians and rheumatologists
caring for these mothers and children, and prompt
appropriate referral for assessment of neuropsychiatric
function. There is increasing recognition that early iden-
tiﬁcation, intervention and treatment, even during
infancy, can improve long-term function in children with
developmental delays.36 Future directions of this
research should include elucidation of mechanistic pro-
cesses associated with antiphospholipid antibodies, and
their effects on fetal neurodevelopment.
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